2023
Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice
Gaidos J, Al Bawardy B, Farraye F, Regueiro M. Use of Standardized Inflammatory Bowel Disease Endoscopy Scores in Clinical Practice. Crohn's & Colitis 360 2023, 5: otad037. PMID: 37559746, PMCID: PMC10407976, DOI: 10.1093/crocol/otad037.Peer-Reviewed Original ResearchMayo endoscopic subscoreEndoscopic scoreEndoscopy scoresCrohn's diseaseRutgeerts scoreChi-square testPouchitis Disease Activity IndexDisease activity indexSimple Endoscopic ScoreEndoscopic scoring systemManagement of patientsPearson's chi-square testMore consistent useIBD practiceEndoscopic subscoreMucosal healingAdult gastroenterologistsMore frequent useUnpaired Student'sClinical practiceTreatment targetsScoring systemWeb-based surveyCase-based conferencesFurther evaluation
2021
Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience
Ramos G, Al-Bawardy B, Neto M, Bledsoe A, Quinn K, Heron V, Willrich M, Johnson A, Chedid V, Coelho-Prabhu N, Kisiel J, Papadakis K, Pardi D, Kane S, Tremaine W, Raffals L, Bruining D, Faubion W, Harmsen W, Loftus E. Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360 2021, 3: otab019. PMID: 36776673, PMCID: PMC9802288, DOI: 10.1093/crocol/otab019.Peer-Reviewed Original ResearchRadiologic responseClinical responseCertolizumab pegolMucosal healingCrohn's diseaseRadiologic healingCD patientsTrough levelsPositive antibody levelsSingle-center experienceCD outcomesAntibody levelsClinical managementOdds ratioCTL levelsHigher oddsRetrospective evaluationPatientsBiochemical responsesClinical practiceQuartile analysisAntibodiesCharacteristic curveOutcomesDisease
2018
Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease
Al-Bawardy B, Ramos GP, Willrich MAV, Jenkins SM, Park SH, Aniwan S, Schoenoff SA, Bruining DH, Papadakis KA, Raffals L, Tremaine WJ, Loftus EV. Vedolizumab Drug Level Correlation With Clinical Remission, Biomarker Normalization, and Mucosal Healing in Inflammatory Bowel Disease. Inflammatory Bowel Diseases 2018, 25: 580-586. PMID: 30165638, DOI: 10.1093/ibd/izy272.Peer-Reviewed Original ResearchConceptsMedian vedolizumab trough levelsVedolizumab trough levelsC-reactive proteinInflammatory bowel diseaseNormal C-reactive proteinMucosal healingCrohn's diseaseUC patientsBowel diseaseTrough levelsUlcerative colitisClinical managementFourth of patientsTrough level measurementMayo endoscopic scoreCross-sectional studyHigh CRP patientsBiomarker normalizationIBD patientsClinical remissionCRP patientsEndoscopic scoreMucosal ulcersDetectable antibodiesBACKGROUND/
2017
Endoscopic and Radiographic Assessment of Crohn's Disease
Al-Bawardy B, Hansel SL, Fidler JL, Barlow JM, Bruining DH. Endoscopic and Radiographic Assessment of Crohn's Disease. Gastroenterology Clinics Of North America 2017, 46: 493-513. PMID: 28838411, DOI: 10.1016/j.gtc.2017.05.005.BooksConceptsCrohn's diseaseFavorable long-term outcomeEndoscopic mucosal healingRadiologic scoring systemChronic inflammatory disordersLong-term outcomesObjective measuresRadiologic responseDisease activityClinical improvementMucosal healingClinical symptomsReduced hospitalizationsInflammatory disordersRadiographic assessmentTreatment targetsScoring systemScoring toolDiseaseMore objective measuresTherapyCorticosteroidsHospitalizationComplicationsInflammation